1. INTRODUCTION
1.1. Market Overview
1.2. Market Definition
1.3. Scope of the Study
1.4. Market Segmentation
1.5. Currency
1.6. Assumptions
1.7. Base and Forecast Years Timeline
1.8. Key Benefits for the Stakeholder
2. RESEARCH METHODOLOGY
2.1. Research Design
2.2. Research Processes
3. EXECUTIVE SUMMARY
3.1. Key Findings
4. MARKET DYNAMICS
4.1. Market Drivers
4.2. Market Restraints
4.3. Porter’s Five Forces Analysis
4.3.1. Bargaining Power of Suppliers
4.3.2. Bargaining Power of Buyers
4.3.3. Threat of New Entrants
4.3.4. Threat of Substitutes
4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis
4.5. Analyst View
5. GLOBAL CANCER VACCINES MARKET BY TECHNOLOGY
5.1. Introduction
5.2. Dendritic Cells (DC) Cancer Vaccines
5.3. Recombinant Cancer Vaccines
5.4. Antigen/Adjuvant Cancer Vaccines
5.5. Whole-Cell Cancer Vaccines
5.6. Viral Vector & DNA Cancer Vaccines
5.7. Others
6. GLOBAL CANCER VACCINES MARKET BY TYPE
6.1. Introduction
6.2. Preventive Cancer Vaccines
6.3. Therapeutic Cancer Vaccines
7. GLOBAL CANCER VACCINES MARKET BY APPLICATION
7.1. Introduction
7.2. Cervical Cancer
7.3. Prostate Cancer
7.4. Others
8. GLOBAL CANCER VACCINES MARKET BY END-USER
8.1. Introduction
8.2. Pediatrics
8.3. Adults
9. GLOBAL CANCER VACCINE MARKET BY GEOGRAPHY
9.1. Introduction
9.2. North America
9.2.1. United States
9.2.2. Canada
9.2.3. Mexico
9.3. South America
9.3.1. Brazil
9.3.2. Argentina
9.3.3. Others
9.4. Europe
9.4.1. UK
9.4.2. Germany
9.4.3. France
9.4.4. Others
9.5. Middle East and Africa
9.5.1. UAE
9.5.2. South Africa
9.5.3. Israel
9.5.4. Saudi Arabia
9.5.5. Others
9.6. Asia Pacific
9.6.1. China
9.6.2. Japan
9.6.3. India
9.6.4. Australia
9.6.5. Taiwan
9.6.6. South Korea
9.6.7. Others
10. COMPETITIVE ENVIRONMENT AND ANALYSIS
10.1. Major Players and Strategy Analysis
10.2. Market Share Analysis
10.3. Mergers, Acquisitions, Agreements, and Collaborations
10.4. Competitive Dashboard
11. COMPANY PROFILES
11.1. AstraZeneca plc
11.2. GlaxoSmithKline plc.
11.3. Merck & Co., Inc.
11.4. Pfizer Inc.
11.5. Moderna Inc.
11.6. OSE Therapeutics
11.7. Nouscom
11.8. OncBioMune Pharmaceuticals Inc.
11.9. Sanofi S.A.
11.10. Bristol-Myers Squibb